Are ABMD & DXCM Neck And Neck? Let's Take A Closer Look
Zacks Investment Research | Dec 16, 2018 09:02PM ET
Medical Instrument companies Abiomed, Inc. (NASDAQ:ABMD) and DexCom, Inc. (NASDAQ:DXCM) are two solid contenders in the U.S. MedTech space, which is expected to reach a worth of $409.5 billion by 2023 at a CAGR of 4.5%. Notably, analysts believe that 2019 is likely to prove profitable for U.S. medical device companies, courtesy of the 2.3% Medical Device tax abatement along with focus on Artificial Intelligence and cybersecurity.
Against this backdrop, it is difficult to choose between the above-mentioned companies as they have similar business models. Making things more difficult, the scales apparently look balanced as Abiomed carries a Zacks Rank #2 (Buy), while DexCom sports a Zacks Rank #1 (Strong Buy). You can see industry has rallied 8.2% in the same time frame. Meanwhile, the S&P 500 index has declined 3.5%.
Which Way Are Estimates Headed?
Earnings
The Zacks Consensus Estimate for Abiomed’s current-quarter earnings per share stands at 93 cents, suggesting an improvement of 32.9% year over year. The same for DexCom is projected at 13 cents, showing year-over-year growth of 30%.
Sales
The Zacks Consensus Estimate for Abiomed’s current-quarter revenues is pegged at $194.88 million, suggesting growth of 26.5% from the previous year. The same for DexCom is pegged at $283.08 million, reflecting a rise of 28.1%.
DexCom, Inc. Price and Consensus
Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 or 2, are better picks than most.
Over the past four years, the company’s revenues have seen a CAGR of 37.2% to $594 million.
Abiomed raised its fiscal 2019 guidance, calling for revenues of $765-$770 million, showing an increase of 29-30% from the previous fiscal.
DexCom also has a Growth Score of A. Over the past four years, the company’s revenues have seen a CAGR of 40.5% to $719 million.
DexCom has also raised the 2018 guidance. The company expects revenues of $975 million against the previous projection of $925 million.
Other Key Picks
Other top-ranked stocks in the broader medical space are Stryker Corporation (NYSE:SYK) and Surmodics, Inc. (NASDAQ:SRDX) .
Stryker has a long-term expected earnings growth rate of 10% and a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Get The News You Want
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.